CAC
SNDX icon

Cowen and Company’s Syndax Pharmaceuticals SNDX Stock Holding History

Cowen and Company’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,700
Closed -$36K – 504
2020
Q2 		$36K Buy
+14,700
New +$224K 0.01% 307

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Cowen and Company's SNDX Position: Q1 2022 in Review

Cowen and Company sold out of Syndax Pharmaceuticals (SNDX) in Q1 2022, closing a stake of 377 shares — an estimated $8K sold.

Cowen and Company first reported a position in SNDX in Q2 2020 and held it in 3 quarters. The position peaked at $389K in Q2 2020. 136 funds tracked by Wall St. Rank hold SNDX as of Q1 2022.

  • Cowen and Company reported no remaining Syndax Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Cowen and Company sold 377 Syndax Pharmaceuticals shares in Q1 2022, an estimated $8K.
  • Cowen and Company first reported a position in Syndax Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Cowen and Company's Syndax Pharmaceuticals position peaked at $389K in Q2 2020.
  • 136 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2022.

Based on Cowen and Company's 13F filing for Q1 2022, filed 16 May 2022.